Search research articles
Contact Us
Filters
Showing results (471-480 of 565) with videos related to
Page
of 57
Sort By:
Circulation. Heart Failure
|
February 8, 2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study
Yee Weng Wong, Laine Thomas, Jie-Lena Sun, et al.
American Heart Journal
|
December 5, 2009
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry
Telly A Meadows, Deepak L Bhatt, Alan T Hirsch, et al.
European Heart Journal. Acute Cardiovascular Care
|
February 25, 2014
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients
Gaetano M De Ferrari, Keith A A Fox, Jennifer A White, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
The Annals of Thoracic Surgery
|
February 20, 2007
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
Abhinav Goyal, John H Alexander, Gail E Hafley, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
American Heart Journal
|
February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
International Journal of Cardiology
|
May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY
Sarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
European Heart Journal
|
March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Page
of 57
Search research articles
Search
Showing results (471-480 of 565) with videos related to
Sort By:
Page
of 57
Circulation. Heart Failure
|
February 8, 2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study
Yee Weng Wong, Laine Thomas, Jie-Lena Sun, et al.
American Heart Journal
|
December 5, 2009
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry
Telly A Meadows, Deepak L Bhatt, Alan T Hirsch, et al.
European Heart Journal. Acute Cardiovascular Care
|
February 25, 2014
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients
Gaetano M De Ferrari, Keith A A Fox, Jennifer A White, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
The Annals of Thoracic Surgery
|
February 20, 2007
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
Abhinav Goyal, John H Alexander, Gail E Hafley, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
American Heart Journal
|
February 3, 2009
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
Adrian F Hernandez, Christopher M O'Connor, Randall C Starling, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
International Journal of Cardiology
|
May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY
Sarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.
European Heart Journal
|
March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
Page
of 57